Safety of Amino Acids
Safety Studies of Amino Acids in Animals
Amino Acid | Animal | Method of administration | Duration (recovery period) |
Dose | Reference | |
Indispensable Amino Acids | ||||||
---|---|---|---|---|---|---|
L-histidine | Fischer rat | Mixed food | 13W | 0.31, 0.62, 1.25, 2.5, 5% (w/w) |
[Japanese] Ikezaki S, Nishikawa A, et al. "13-week subchronic toxicity study of L-histidine monohydrochloride in F344 rats" Bull Natl Ins Health Sci (1994), 112:57-63 |
|
L-isoleucine | SD rat | Mixed food | 13W (5W) | 1.25, 2.5, 5% (w/w) |
Tsubuku S, Hatayama K, et al. “Thirteen-week oral toxicity study of branched-chain amino acids in rats” Int J Toxicol (2004), 23(2):119-126 |
|
L-leucine | SD rat | Mixed food | 13W (5W) | 1.25, 2.5, 5% (w/w) |
Tsubuku S, Hatayama K, et al. “Thirteen-week oral toxicity study of branched-chain amino acids in rats” Int J Toxicol (2004), 23(2):119-126 |
|
L-lysine/HCl | SD rat | Mixed food | 13W (5W) | 1.25, 2.5, 5% (w/w) |
Tsubuku S, Mochizuki M, et al. “Thirteen-week oral toxicity study of L-lysine hydrochloride in rats” Int J Toxicol (2004), 23(2):113-118 |
|
L-methionine | Fischer rat ♂ | Mixed food | 4W | 0.1, 0.3, 0.9, 2.7% (w/w) |
Chin K, Toue S, et al. "A 4-week toxicity study of methionine in male rats" Int J Toxicol (2015), 34(3):233-241 |
|
L-phenylalanine | SD rat | Mixed food | 28 days | 0.5, 1.5, 5.0% |
Shibui Y, Miwa T, et al. "28-Day dietary toxicity study of L-phenylalanine in rats" Fund Toxicol Sci (2014), 1(2):29-38 |
|
L-threonine | SD rat | Mixed food | 13W (5W) | 1.25, 2.5, 5.0% |
Aoki M, Ishida S, et al. "A 13-week feeding toxicity study of L-threonine in rats with a recovery period of 5 weeks" Fund Toxicol Sci (2014), 1(2):49-62 |
|
L-tryptophan | SD rat | Mixed food | 13W (5W) | 1.25, 2.5, 5.0% |
Shibui Y, Matsumoto H, et al. +LOAEL(mg/kg/day) was calicurated using original research data (BW for LOAEL). "Thirteen week toxicity study of dietary L‐tryptophan in rats with a recovery period of 5 weeks" J Appl Toxicol (2018), 38(4): 552-563 |
|
L-valine | SD rat | Mixed food | 13W (5W) | 1.25, 2.5, 5% (w/w) |
Tsubuku S, Hatayama K, et al. “Thirteen-week oral toxicity study of branched-chain amino acids in rats” Int J Toxicol (2004), 23(2):119-126 |
|
Dispensable Amino Acids | ||||||
L-alanine | SD rat | Gavage | 4W (2W) | 2,000mg/kg/day |
Aoki M, Mochizuki M, et al. “A 4-week oral toxicity study of L-alanine in rats with a recovery period of 2 weeks” Fund Toxicol Sci (2014), 1(2):63-72 |
|
L-arginine | SD rat | Mixed food | 13W (5W) | 1.25, 2.5, 5% (w/w) |
Tsubuku S, Hatayama K, et al. “Thirteen-week oral toxicity study of L-arginine in rats” Int J Toxicol (2004), 23(2):101-105 |
|
Pig | Mixed food twice a day | 13W | 1.21, 1.81, 2.42% (w/w) |
Hu S, Li X, et al. “Safety of long-term dietary supplementation with L-arginine in pigs” Amino Acids (2015), 47(5):925-936 |
||
Mixed food twice a day | 13W | 1.0, 1.5, 2.0% (w/w) |
||||
SD rat | Drinking water |
13W | 2.18, 4.35 g/kg/day |
Yang Y, Wu Z, et al. “Safety of long‑term dietary supplementation with L‑arginine in rats” Amino Acids (2015), 47(9):1909-1920 |
||
L-asparagine | Fischer rat | Mixed food | 90 days | 1.25, 2.5, 5% (w/w) |
Yokohira M, Hosokawa K, et al. "A 90-day toxicity study of L-asparagine, a food additive, in F344 rats" Food Chem Toxicol (2008), 46(7):2568-2572 |
|
L-aspartic acid | Fischer rat | Mixed food | 90 days | 0.05, 1.25, 2.5, 5.0% (w/w) |
Tada Y, Yano N, et al. "Toxic effects of L-aspartic acid at high dose levels on kidneys and salivary glands in Fischer 344 rats detected in a 90-day feeding study" Food Chem Toxicol (2008), 46(8):2789-2795 |
|
L-cysteine | SD rat | Gavage | 4W | 500, 1000, 2000 mg/kg/day |
Shibui Y, Sakai R, et al. "Comparisons of L-cysteine and D-cysteine toxicity in 4-week repeated-dose toxicity studies of rats receiving daily oral administration" J Toxicol Pathol (2017), 30(3):217-229 |
|
L-glutamate | - | - | - | - |
Acceptable daily intake (ADI) is not specified in JECFA report. ADI can be driven from NOAEL, so that NOAEL of L-Glu/Na is not also specified.: Principles for the safety assessment of food additives and contaminants in food. World Health Organization International Program on Chemical Safety in Cooperation with the Joint FAO/WHO Expert Committee on Food Additives, Geneva, Environmental Health Criteria 70 (1987). |
|
CD-1 mouse | Mixed food |
3-genaration reproductive toxicity: F0:Gestation & lactation F1: Postweaning – Lactation F2: Postweaning – Lactation F3: Birth - Weaning |
1.0, 4.0% (w/w) |
Anantharaman K “In utero and dietary administration of monosodium L-glutamate to mice: Reproductive performance and development in a multigeneration study” Glutamic Acid: Advances in Biochemistry and Physiology, ed. by Filer LJ, et al., Raven Press, NY (1979):231-253 |
||
L-glutamine | SD rat | Mixed food | 13W (5W) | 1.25, 2.5, 5% (w/w) |
Tsubuku S, Hatayama K, et al. “Thirteen-week oral toxicity study of L-glutamine in rats.” Int J Toxicol (2004), 23(2):107-112 |
|
L-glycine | SD rat | Gavage | 28 days | 500, 1000, 2000 mg/kg/day |
Shibui Y, Miwa T, et al. "A 4-week repeated dose toxicity study of glycine in rats by gavage administration" J Toxicol Pathol (2013), 26(4) 405–412, 2013 |
|
L-proline | Fischer rat | Mixed food | 90 days | 0.625, 1.25, 2.5, 5.0% |
Tada Y, Yano N, et al. "Toxicological evaluation of L-proline in a 90-day feeding study with Fischer 344 rats" Regul Toxicol Pharmacol (2010), 58(1):114-120 |
|
L-serine | SD rat | Gavage | 13W | 500, 1500, 3000 mg/kg/day |
Kaneko I, Han L, et al. "A 13-week subchronic oral toxicity study of L-serine in rats" Food Chem Toxicol (2009), 47(9):2356-2360 |
|
Fischer rat | Mixed food | 90 days | 0.06, 0.5, 1.5, 5.0% |
Tada Y, Yano N, et al. "A 90-day feeding toxicity study of L-serine in male and female Fischer 344 rats" J Toxicol Pathol (2010), 23(1):39-47 |
||
L-tyrosine | SD rat | Gavage | 13W | 200, 600, 2000 mg/kg/day |
Shibui Y, Manabe Y, et al. "13-week repeated dose toxicity study of l-tyrosine in rats by daily oral administration" Food Chem Toxicol (2016), 87:55-64 |
|
Non-code protein Amino Acids | ||||||
L-ornithine | SD rat | Mixed food | 13W (5W) | 1.25, 2.5, 5.0% |
Ishida S, Sarada M, et al. "Genotoxicity and subchronic oral toxicity of L-ornithine monohydrochloride" Regul Toxicol Pharmacol (2013), 67(3):360-71 |
|
L-citrulline | SD rat | Gavage | 4W | 2000 mg/kg/day |
Morita M, Yamaguchi T, et al. "A 4-week oral gavage toxicity study of L-citrulline in rats" Fund Toxicol Sci (2017), 4(5):219-227 |
|
L-hydroxyproline | SD rat | Gavage | 28 days (14 days) | 40, 200, 1000, 4000 mg/kg/day |
Akiduki S, Kawada Y, et al. “Twenty-eight-day oral toxicity study of L-hydroxyproline in rats with 14-day post-treatment observation period” Fund Toxicol Sci (2019), 6(3):65-74 |
Safety Studies of Amino Acids in Human
Amino Acid | Category | Subject | Method of administration | Duration | Dose | Reference | |
Review | |||||||
---|---|---|---|---|---|---|---|
Amino acids | Safety Review | - | - | - | - |
Elango R. Tolerable Upper Intake Level for Individual Amino Acids in Humans: A Narrative Review of Recent Clinical Studies Advances in Nutrition (2023), 14(4): 885-894. |
|
Safety Review | - | - | - | - | Blachier F, et al. Tolerable amounts of amino acids for human supplementation: summary and lessons from published peer-reviewed studies Amino Acids (2021) 53(9):1313-1328 |
||
Indispensable Amino Acids | |||||||
L-histidine | Safety Assessment Study | Healthy adults (male and female) | Oral | 4W | 4, 8, 12, 16 g/day |
Gheller ME, et al. Tolerance to graded dosages of histidine supplementation in healthy human adults American Journal of Clinical Nutrition (2020), 112(5): 1358-1367. |
|
Safety Review | - | - | - | - |
Thalacker-Mercer AE, et al. Benefits and Adverse Effects of Histidine Supplementation The Journal of Nutrition (2020), 150(Suppl1), 2588S-2592S. |
||
Safety Review | - | - | - | - |
Cynober L, et al. Proposals for Upper Limits of Safe Intake for Methionine, Histidine, and Lysine in Healthy Humans The Journal of Nutrition (2020)150(Suppl1):2606S-2608S, |
||
L-isoleucine | |||||||
L-leucine | Safety Assessment Study | Healthy adults (male) | Oral | Once | 50, 150, 250, 500, 750, 1000, 1250 mg/kg/day |
Elango R, et al. Determination of the tolerable upper intake level of leucine in acute dietary studies in young men American Journal of Clinical Nutrition (2012), 96(4):759-767. |
|
Safety Review | - | - | - | - |
Cynober L, et al. Proposals for Upper Limits of Safe Intake for Arginine and Tryptophan in Young Adults and an Upper Limit of Safe Intake for Leucine in the Elderly The Journal of Nutrition (2016), 146(12):2652S-2654S. |
||
Safety Review | - | - | - | - |
Pencharz PB, et al. Determination of the tolerable upper intake level of leucine in adult men The Journal of Nutrition (2012), 142(12):2220S-2224S. |
||
L-lysine/HCl | Safety Review | - | - | - | - |
Hayamizu K, et al. Safety assessment of L-lysine oral intake: a systematic review Amino Acids (2019), 51(4):647-659. |
|
Safety Review | - | - | - | - |
Cynober L, et al. Proposals for Upper Limits of Safe Intake for Methionine, Histidine, and Lysine in Healthy Humans The Journal of Nutrition (2020)150(Suppl1):2606S-2608S, |
||
L-methionine | Safety Assessment Study | Healthy older adults | Oral | 4W | 9.2, 22.5, 46.3, 91 mg/kg/day |
Deutz NE, et al. Tolerance to increased supplemented dietary intakes of methionine in healthy older adults American Journal of Clinical Nutrition (2017) 106(2):675-683. |
|
Safety Review | - | - | - | - |
Ligthart-Melis GC. et al. Metabolic Consequences of Supplemented Methionine in a Clinical Context The Journal of Nutrition (2020)150(Suppl1):2538S-2547S, |
||
Safety Review | - | - | - | - |
Cynober L, et al. Proposals for Upper Limits of Safe Intake for Methionine, Histidine, and Lysine in Healthy Humans The Journal of Nutrition (2020)150(Suppl1):2606S-2608S, |
||
Case Study | Patients with coronary artery or peripheral arterial disease | Oral | Once | 100 mg/kg |
Krupkova-Meixnerova L, et al. Methionine-loading test: evaluation of adverse effects and safety in an epidemiological study Nutrition(2002), 21(2):151-156. |
||
Case Study | Healthy nonsmoking adults and patients with several thrombotic conditions. | Oral | Once | 100 mg/kg |
Majluf-Cruz A, et al. Safety of the oral methionine load test: effects on the clinical performance and laboratory tests Revista de Investigacion Clinica (2013), 65(4):323-330. |
||
L-phenylalanine | Safety Assessment Study | Healthy adults (male) | Oral | 4W | 3, 6, 9, 12 g/day |
Miura N. et al. Subchronic Tolerance Trials of Graded Oral Supplementation with Phenylalanine or Serine in Healthy Adults Nutrients (2021) 13(6): 1976 |
|
Safety Review | - | - | - | - |
Blachier F, et al. Tolerable amounts of amino acids for human supplementation: summary and lessons from published peer-reviewed studies Amino Acids (2021) 53(9):1313-1328 |
||
Case Study | Healthy, active male | Oral | Once | 3g |
Ueda K. et al. The effects of phenylalanine on exercise-induced fat oxidation: a preliminary, double-blind, placebo-controlled, crossover trial Journal of the International Society of Sports Nutrition (2017), 14:34. |
||
L-threonine | Case Study | Patients with familial spastic paraparesis (FSP) | Oral | 2W | 4.5, 6 g/day |
Growdon J.H. et al. L-Threonine in the Treatment of Spasticity Clinical neuropharmacology (1991), 14(5):403-412. |
|
Case Study | Patients with spinal spasticity | Oral | - | 6 g/day |
Lee A. and Patterson V. A double-blind study of L-threonine in patients with spinal spasticity Acta Neurologica Scandinavica (1993), 88(5):334-338. |
||
Case Study | Patients with amyotrophic lateral sclerosis (ALS) | Oral | 6M | 4 g/day |
Tandan R. et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis Neurology (1996), 47(5):1220-1226. |
||
L-tryptophan | Safety Assessment Study | Healthy Japanese women | Oral | 21D | 1, 2, 3, 4, 5 g/day |
Hiratsuka C, et al. Supplementing healthy women with up to 5.0 g/d of L-tryptophan has no adverse effects The Journal of Nutrition (2013), 143(6):859-866 |
|
Safety Review | - | - | - | - |
Cynober L, et al. Proposals for Upper Limits of Safe Intake for Arginine and Tryptophan in Young Adults and an Upper Limit of Safe Intake for Leucine in the Elderly The Journal of Nutrition (2016), 146(12): 2652S-2654S. |
||
L-valine | |||||||
Dispensable Amino Acids | |||||||
L-alanine | Case Study | Therapeutically starved obese subjects | Oral | 1D | 50 g |
Genuth SM. Effects of oral alanine administration in fasting obese subjects Metabolism. 22(7), 1973, 927-937. |
|
L-arginine | Safety Review | - | - | - | - |
Cynober L, et al. Proposals for Upper Limits of Safe Intake for Arginine and Tryptophan in Young Adults and an Upper Limit of Safe Intake for Leucine in the Elderly The Journal of Nutrition (2016), 146(12): 2652S-2654S. |
|
Safety Review | - | - | - | - |
Shao A, et al. Risk assessment for the amino acids taurine, L-glutamine and L-arginine Regulatory Toxicology and Pharmacology (2008), 50(3):376-399, |
||
Safety Assessment Study | Adults (male and female) | Oral | 90D | 0, 15, 30 g/day |
McNeal CJ, et al. Safety of dietary supplementation with arginine in adult humans. Amino Acids (2018), 50(9):1215-1229. |
||
L-asparagine | |||||||
L-aspartic acid | Case Study | - | Oral | - | 5, 10 g |
Harold EC. et al. Stimulation of pituitary hormone secretion by neurotransmitter amino acids in humans. Metabolism. 38(12), 1989, 1179-1182. |
|
L-cysteine | Case Study | - | Oral | - | 5, 10 g |
Harold EC. et al. Stimulation of pituitary hormone secretion by neurotransmitter amino acids in humans. Metabolism. 38(12), 1989, 1179-1182. |
|
L-glutamate | Safety Review | - | - | - | - | Acceptable daily intake (ADI) is not specified in JECFA report. ADI can be driven from NOAEL, so that NOAEL of L-Glu/Na is not also specified.: Principles for the safety assessment of food additives and contaminants in food. World Health Organization | |
Safety Review | - | - | - | - | International Program on Chemical Safety in Cooperation with the Joint FAO/WHO Expert Committee on Food Additives, Geneva, Environmental Health Criteria 70 (1987). | ||
L-glutamine | Safety Assessment Study | Healthy adults (male), HIV patients with AIDS-associated weight loss and cancer patients with wasting | Oral | - | 14 g |
Rathmacher JA. et al. Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters Journal of Parenteral and enteral nutrition (2004) 28(2):65-75. |
|
Safety Review | - | - | - | - |
Shao A, et al. Risk assessment for the amino acids taurine, L-glutamine and L-arginine Regulatory Toxicology and Pharmacology (2008), 50(3):376-399, |
||
Case Study | Healthy adults (male) | Oral | 1D | 0.3, 0.6, 0.9 g/kg·FFM |
Ogden HB, et al. Gastrointestinal Tolerance of Low, Medium and High Dose Acute Oral l-Glutamine Supplementation in Healthy Adults: A Pilot Study Nutrients (2020) 12(10):2953. |
||
Glycine | Safety Assessment Study | Healthy adults (male and female) | Oral | 7D | 9 g/day |
Inagawa K, et al. Assessment of Acute Adverse Events of Glycine Ingestion at a High Dose in Human Volunteers Journal of Urban Living and Health Association (2006), 50(1):27-32. |
|
L-proline | |||||||
L-serine | Safety Assessment Study | Healthy adults (male) | Oral | 4W | 3, 6, 9, 12 g/day |
Miura N. et al. Subchronic Tolerance Trials of Graded Oral Supplementation with Phenylalanine or Serine in Healthy Adults Nutrients (2021) 13(6): 1976 |
|
Safety Review | - | - | - | - |
Blachier F, et al. Tolerable amounts of amino acids for human supplementation: summary and lessons from published peer-reviewed studies Amino Acids (2021) 53(9):1313-1328 |
||
L-tyrosine | Case Study | Patients with essential hypertension | Oral | 2W | 7.5 g/day |
Sole MJ. Et al. Chronic dietary tyrosine supplements do not affect mild essential hypertension Hypertension (1985), 7(4):593-596. |
|
Case Study | Subjects with narcolepsy and cataplexy | Oral | 4W | 9 g/day |
Elwes RDC. et al. Treatment of narcolepsy with L-tyrosine: double-blind placebo-controlled trial The Lancet (1989), 334(8671):1067-1069. |
||
Case Study | - | Oral | 1D | 150 mg/day |
Neri DF. et al. The effects of tyrosine on cognitive performance during extended wakefulness Aviation, Space and Environmental Medicine (1995), 66(4):313-319. |
||
Case Study | Patients with nemaline myopathy | Oral | - | 250 to 3000 mg/day |
Monique MR. et al. Dietary L-tyrosine supplementation in nemaline myopathy Journal of Child Neurology (2008),23(6):609-13. |
||
Non-code protein Amino Acids | |||||||
L-ornithine/HCl | Safety Assessment Study | Healthy adults (male) | Oral | 4W | 3.2, 6, 9.2, 12 g/day |
Miura N. et al. Subchronic tolerance trials of graded oral supplementation with ornithine hydrochloride or citrulline in healthy adults Amino Acid (2022); 1-13. |
|
Case Study | Healthy adults (male and female) | Oral | - | 2000 mg/day for 7D and 6000 mg/day for 1D |
Sugino T. et al. L-ornithine supplementation attenuates physical fatigue in healthy volunteers by modulating lipid and amino acid metabolism Nutrition Research (2008), 28(11):738-743. |
||
L-citruline | Safety Assessment Study | Healthy adults (male) | Oral | 4W | 6, 12, 18, 24 g/day |
Miura N. et al. Subchronic tolerance trials of graded oral supplementation with ornithine hydrochloride or citrulline in healthy adults Amino Acid (2022); 1-13. |
|
Case Study | Healthy adults (male) | Oral | 1D | 2, 5, 10, 15 g |
Moinard C. et al. Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study British Journal of Nutrition (2008), 99(4):855-862. |
||
L-hydroxyproline |